Reflections on defining pulmonary embolism outcomes in today’s evolving practice, including most meaningful endpoints, pros and cons of RV/LV ratio and composite endpoints, and patient and payer ...

Less than half of the recent trials testing therapies for atherosclerotic cardiovascular disease (ASCVD) use the same endpoint, and many alter those endpoints after enrollment begins, according to a ...

Clinical trials remain the cornerstone of evidence-based medicine, with composite endpoints playing an increasingly pivotal role in assessing the efficacy and safety of new interventions. Composite ...

"We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path ...

Shelley Wood: Hi. I am Shelley Wood, Managing Editor of heartwire, and my guests today are Dr. Mega and Dr. Ohman. Our topic is negative or neutral trials that have positive (or at least interesting) ...